| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b0c3ee528fc1c179aca30a2b0a743cb3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 |
| filingDate |
2018-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ce0c4f39dd4027c1c754f28e845cbd4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9ac984fc06ee20412858352263060ff |
| publicationDate |
2021-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-I734027-B |
| titleOfInvention |
Therapeutic combination and method for treating cancer |
| abstract |
A therapeutic combination for treating cancer in a subject having a tumor is provided. The therapeutic combination includes an immunotherapeutics for treating the cancer. And a peptide having one of SEQ ID NOs. 1-3 and being capable of selectively binding to CXC chemokine receptor 4 (CXCR4). When the peptide of the therapeutic combination binds to CXCR4, and immune microenvironment of the tumor is modulated and/or accessibility of immune cells to the tumor is regulated. A method for treating cancer using the therapeutic combination is also provided. |
| priorityDate |
2017-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |